Vanguard Personalized Indexing Management LLC Has $449,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Vanguard Personalized Indexing Management LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 26.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,643 shares of the company’s stock after purchasing an additional 5,831 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Teva Pharmaceutical Industries were worth $449,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Janney Montgomery Scott LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 13.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock worth $19,366,000 after acquiring an additional 164,614 shares in the last quarter. QRG Capital Management Inc. boosted its stake in Teva Pharmaceutical Industries by 53.7% in the first quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after purchasing an additional 50,247 shares in the last quarter. Capital Wealth Planning LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $2,169,000. Public Employees Retirement Association of Colorado increased its stake in shares of Teva Pharmaceutical Industries by 1,382.8% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock valued at $2,671,000 after buying an additional 238,573 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Teva Pharmaceutical Industries by 12.0% in the first quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after buying an additional 65,529 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the sale, the insider now owns 45,060 shares in the company, valued at approximately $777,285. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $17.46 on Friday. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. Teva Pharmaceutical Industries Limited has a 52 week low of $8.06 and a 52 week high of $19.08. The stock has a market capitalization of $19.78 billion, a P/E ratio of -42.59, a price-to-earnings-growth ratio of 1.23 and a beta of 0.88. The stock has a fifty day moving average of $17.75 and a 200-day moving average of $16.18.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. On average, sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 23rd. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Wednesday, July 10th. Jefferies Financial Group raised their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Finally, UBS Group boosted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $18.89.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.